Big Lots Posts Wider-than Expected Q3 Loss, Sees Weak Q4 Comps; Stock Down In Pre-market

Home discount retailer Big Lots, Inc. (BIG), while reporting wider net loss and weak sales in its third quarter on Thursday, said it expects fourth-quarter comps to be down in the low-double-digit range.

Net new stores will add about 170 basis points of growth versus 2021. The company expects the fourth quarter gross margin rate to improve sequentially but remain in the mid-30s range.

In its third quarter, Big Lots reported a net loss of $103.01 million or $3.56 per share, wider than net loss of $4.33 million or $0.14 per share a year ago.

Adjusted net loss for the latest quarter was $86.7 million, or $2.99 per share.

On average, eight analysts polled by Thomson Reuters expected loss of $2.94 per share for the quarter. Analysts' estimates typically exclude special items.

Net sales for the third quarter totaled $1.20 billion, a 9.8 percent decrease compared to $1.34 billion for the same period last year. Analysts estimated sales of $1.21 billion for the quarter.

The decline was driven by a comparable sales decrease of 11.7 percent.

In pre-market activity on the NYSE, Big Lots shares were losing around 6.7 percent to trade at $18.20.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Consumer Product Safety Commission or CPSC announced recall of thousands of children's Robes made in China and sold exclusively on Amazon.com by various companies. The recalled robes fail to meet the federal flammability standards for children's sleepwear, posing a risk of burn injuries to children. Further, citing the same concerns, Paper Cape children's pajamas manufactured in Peru ... Health services company Cigna Corp. reported Friday higher profit in its fourth quarter reflecting growth in both Evernorth and Cigna Healthcare segments. Adjusted earnings and topline beat market estimates. Looking ahead for fiscal 2023, the company projects adjusted earnings and adjusted revenues to be higher than last year, but below market view. French drug major Sanofi SA reported Friday higher profit in its fourth quarter with strong revenue growth mainly with strong sales of Dupixent. Looking ahead for fiscal 2023, the company projects higher business earnings, but the expected growth is slower than recorded in fiscal 2022. Sanofi shares were losing around 4 percent in the morning trading in Paris as well as in pre-market activity...
Follow RTT